Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: Long-term results of a prospective phase 1/2 study

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 5, 2013, Pages 992-999

  Fokas, Emmanouil ^a   Conradi, Lena ^b   Weiss, Christian ^a   Sprenger, Thilo ^b   Middel, Peter ^b   Rau, Tillman ^c   Dellas, Kathrin ^d   Kitz, Julia ^b   Rödel, Franz ^a   Sauer, Rolf ^e   Rüschoff, Josef ^f   Beissbarth, Tim ^b   Arnold, Dirk ^g   Ghadimi, B Michael ^b   Rödel, Claus ^a   Liersch, Torsten ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f Targos Molecular Pathology GmbH   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIATION THERAPIES; COMPLETE RESPONSE; DISEASE-FREE SURVIVAL; HISTOPATHOLOGICAL EXAMINATIONS; LONG-TERM RESULTS; METHODS AND MATERIALS; PREDICTIVE FACTORS; PREOPERATIVE CHEMORADIATION;

DISEASES; SURGERY;

CHEMORADIOTHERAPY;

CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; OXALIPLATIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; RECTUM CARCINOMA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEASIBILITY STUDY; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PREOPERATIVE CARE; PROCEDURES; PROSPECTIVE STUDY; RECTAL NEOPLASMS; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECTAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84888295577     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.09.011     Document Type: Article

References (28)

1. M. Baumann, M. Krause, and E. Dikomey EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms Radiother Oncol 83 2007 238 248
2. D. Azria, F. Bibeau, and N. Barbier Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer BMC Cancer 5 2005 62
3. F. Bertolini, S. Chiara, and C. Bengala Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 73 2009 466 472
4. F. Marquardt, F. Rodel, and G. Capalbo Molecular targeted treatment and radiation therapy for rectal cancer Strahlenther Onkol 185 2009 371 378
5. J.P. Machiels, C. Sempoux, and P. Scalliet Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann Oncol 18 2007 738 744
6. C. Rodel, D. Arnold, and M. Hipp Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer Int J Radiat Oncol Biol Phys 70 2008 1081 1086
7. K. Horisberger, A. Treschl, and S. Mai Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial Int J Radiat Oncol Biol Phys 74 2009 1487 1493
8. C. Weiss, D. Arnold, and K. Dellas Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials Int J Radiat Oncol Biol Phys 78 2010 472 478
9. P.L. Sun, B. Li, and Q.F. Ye Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study Int J Colorectal Dis 27 2012 1325 1332
10. S.Y. Kim, Y.S. Hong, and D.Y. Kim Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase 2 study Int J Radiat Oncol Biol Phys 81 2011 677 683
11. V. Velenik, J. Ocvirk, and I. Oblak Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial Radiol Oncol 46 2012 252 257
12. A. Debucquoy, K. Haustermans, and A. Daemen Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer J Clin Oncol 27 2009 2751 2757
13. M.K. Nyati, M.A. Morgan, and F.Y. Feng Integration of EGFR inhibitors with radiochemotherapy Nat Rev Cancer 6 2006 876 885
14. R. Glynne-Jones, S. Mawdsley, and M. Harrison Cetuximab and chemoradiation for rectal cancer - is the water getting muddy? Acta Oncol 49 2010 278 286
15. P. Erben, P. Strobel, and K. Horisberger KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 81 2011 1032 1038
16. C. Bengala, S. Bettelli, and F. Bertolini Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer Ann Oncol 20 2009 469 474
17. O. Dworak, L. Keilholz, and A. Hoffmann Pathological features of rectal cancer after preoperative radiochemotherapy Int J Colorectal Dis 12 1997 19 23
18. C. Jakob, D.E. Aust, and W. Meyer Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer J Pathol 204 2004 562 568
19. C.J. Woodall, N.J. Watt, and G.B. Clements Simple technique for detecting RNA viruses by PCR in single sections of wax embedded tissue J Clin Pathol 46 1993 276 277
20. R.F. Bonner, M. Emmert-Buck, and K. Cole Laser capture microdissection: molecular analysis of tissue Science 278 1997 1481 1483
21. S. Merkelbach-Bruse, W. Dietmaier, and L. Fuzesi Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors BMC Med Genet 11 2010 106
22. A. Hartley, K.F. Ho, and C. McConkey Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials Br J Radiol 78 2005 934 938
23. M. Maas, P.J. Nelemans, and V. Valentini Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 11 2010 835 844
24. A. Dewdney, D. Cunningham, and J. Tabernero Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) J Clin Oncol 30 2012 1620 1627
25. A. Debucquoy, J.P. Machiels, and W.H. McBride Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation Clin Cancer Res 16 2010 2709 2714
26. C. Pinto, F. Di Fabio, and E. Maiello Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study) Ann Oncol 22 2011 2424 2430
27. J. Gaedcke, M. Grade, and K. Jung KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy Radiother Oncol 94 2010 76 81
28. S.Y. Kim, E.K. Shim, and H.Y. Yeo KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials Int J Radiat Oncol Biol Phys 85 2013 201 207